Growth I. L.P. M33 Sells 673,676 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Growth I. L.P. M33 sold 673,676 shares of Oncology Institute stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $3.05, for a total transaction of $2,054,711.80. Following the sale, the director now owns 13,950,557 shares of the company's stock, valued at approximately $42,549,198.85. The trade was a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Oncology Institute Price Performance

Shares of TOI stock traded down $0.21 during trading hours on Thursday, hitting $2.65. The company's stock had a trading volume of 1,305,964 shares, compared to its average volume of 1,009,592. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. The business has a fifty day moving average of $2.59 and a 200-day moving average of $1.31. The Oncology Institute, Inc. has a twelve month low of $0.13 and a twelve month high of $3.50. The stock has a market cap of $236.47 million, a price-to-earnings ratio of -3.40 and a beta of 0.13.

Oncology Institute (NASDAQ:TOI - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.18) earnings per share for the quarter. The company had revenue of $104.41 million for the quarter. Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC increased its stake in Oncology Institute by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company's stock valued at $56,000 after purchasing an additional 12,000 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Oncology Institute by 49.5% during the 1st quarter. XTX Topco Ltd now owns 55,698 shares of the company's stock valued at $63,000 after acquiring an additional 18,448 shares during the last quarter. Citizens Financial Group Inc. RI purchased a new position in shares of Oncology Institute during the 1st quarter worth about $71,000. WealthShield Partners LLC acquired a new stake in shares of Oncology Institute in the first quarter worth approximately $80,000. Finally, Jane Street Group LLC boosted its position in shares of Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company's stock worth $39,000 after acquiring an additional 109,769 shares during the last quarter. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, BTIG Research began coverage on shares of Oncology Institute in a research report on Thursday, May 15th. They issued a "buy" rating and a $7.00 price objective on the stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.